Major Estimate Revision • May 20
Consensus EPS estimates upgraded to US$1.40 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.68 to -US$1.40 per share. Revenue forecast steady at US$54.1m. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 4.4% to US$2.15 over the past week. Reported Earnings • May 15
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: US$0.53 loss per share (down from US$0.64 profit in 3Q 2025). Revenue: US$12.4m (down 33% from 3Q 2025). Net loss: US$5.62m (down 243% from profit in 3Q 2025). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 3.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. 공시 • May 07
Aytu BioPharma, Inc. to Report Q3, 2026 Results on May 13, 2026 Aytu BioPharma, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on May 13, 2026 Major Estimate Revision • Apr 19
Consensus EPS estimates upgraded to US$1.68 loss, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$57.1m to US$54.0m. 2026 losses expected to reduce from -US$1.90 to -US$1.68 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$9.67 to US$9.33. Share price was steady at US$2.60 over the past week. Major Estimate Revision • Feb 10
Consensus EPS estimates fall by 85%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$55.3m to US$59.1m. Forecast EPS reduced from -US$1.03 to -US$1.90 per share. Pharmaceuticals industry in the US expected to see average net income growth of 1.6% next year. Consensus price target of US$9.33 unchanged from last update. Share price fell 13% to US$2.29 over the past week. New Risk • Feb 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$25m Forecast net loss in 2 years: US$432k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$432k net loss in 2 years). Market cap is less than US$100m (US$25.7m market cap). Reported Earnings • Feb 04
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: US$1.06 loss per share (down from US$0.11 profit in 2Q 2025). Revenue: US$15.2m (down 6.5% from 2Q 2025). Net loss: US$10.6m (down US$11.2m from profit in 2Q 2025). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 75%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. 공시 • Jan 28
Aytu BioPharma, Inc. to Report Q2, 2026 Results on Feb 03, 2026 Aytu BioPharma, Inc. announced that they will report Q2, 2026 results After-Market on Feb 03, 2026 Major Estimate Revision • Jan 22
Consensus EPS estimates upgraded to US$1.03 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$1.14 to -US$1.03 per share. Revenue forecast unchanged from US$55.3m at last update. Pharmaceuticals industry in the US expected to see average net income growth of 1.1% next year. Consensus price target of US$9.33 unchanged from last update. Share price was steady at US$2.71 over the past week. New Risk • Nov 16
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.6m net loss in 2 years). Market cap is less than US$100m (US$21.3m market cap). 공시 • Nov 06
Aytu BioPharma, Inc. to Report Q1, 2026 Results on Nov 13, 2025 Aytu BioPharma, Inc. announced that they will report Q1, 2026 results After-Market on Nov 13, 2025 공시 • Oct 27
Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025 Aytu BioPharma, Inc., Annual General Meeting, Dec 10, 2025. Location: 7900 east union avenue, suite 920, colorado 80237, denver United States Major Estimate Revision • Sep 30
Consensus revenue estimates fall by 22% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$70.5m to US$55.2m. Forecast losses increased from -US$0.85 to -US$1.55 per share. Pharmaceuticals industry in the US expected to see average net income decline 3.2% next year. Consensus price target down from US$9.67 to US$9.17. Share price fell 25% to US$1.88 over the past week. Reported Earnings • Sep 24
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: US$2.26 loss per share (improved from US$2.86 loss in FY 2024). Revenue: US$66.4m (down 18% from FY 2024). Net loss: US$14.2m (loss narrowed 11% from FY 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. 공시 • Sep 17
Aytu BioPharma, Inc. to Report Q4, 2025 Results on Sep 23, 2025 Aytu BioPharma, Inc. announced that they will report Q4, 2025 results After-Market on Sep 23, 2025 Breakeven Date Change • Jun 30
Forecast breakeven date pushed back to 2026 The analyst covering Aytu BioPharma previously expected the company to break even in 2025. New forecast suggests the company will make a profit of US$1.66m in 2026. Average annual earnings growth of 77% is required to achieve expected profit on schedule. New Risk • Jun 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$17.5m market cap). 공시 • Jun 03
Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Aytu BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 6,741,573
Price\Range: $1.78
Discount Per Security: $0.1246
Security Name: Prefunded Warrants
Security Type: Equity Warrant
Securities Offered: 6,741,573 Reported Earnings • May 15
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$0.64 (up from US$0.52 loss in 3Q 2024). Revenue: US$18.5m (up 2.6% from 3Q 2024). Net income: US$3.94m (up US$6.83m from 3Q 2024). Profit margin: 21% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. 공시 • May 08
Aytu BioPharma, Inc. to Report Q3, 2025 Results on May 14, 2025 Aytu BioPharma, Inc. announced that they will report Q3, 2025 results After-Market on May 14, 2025 공시 • Mar 31
Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025 Aytu BioPharma, Inc., Annual General Meeting, May 21, 2025. Location: at the office of aytu biopharma, inc., 7900 east union avenue, suite 920, colorado 80237, denver United States Reported Earnings • Feb 13
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$0.11. Revenue: US$16.2m (down 14% from 2Q 2024). Net income: US$665.0k (up 7.4% from 2Q 2024). Profit margin: 4.1% (up from 3.3% in 2Q 2024). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Nov 15
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: US$0.18 (up from US$1.48 loss in 1Q 2024). Revenue: US$16.6m (down 25% from 1Q 2024). Net income: US$1.09m (up US$9.21m from 1Q 2024). Profit margin: 6.6% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 7.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%. 공시 • Nov 14
Aytu Biopharma, Inc. Announces Chief Financial Officer Changes Aytu BioPharma, Inc. announced the promotion of Ryan Selhorn, current Executive Vice President of Finance and Business Optimization, to the role of Chief Financial Officer, replacing Mark Oki, who will depart the company. Prior to Ryan's appointment as Chief Financial Officer, he served as Aytu's Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Ryan was Aytu's Senior Vice President, Finance and Operations, Consumer Healthcare Division from February 2022 to November 2022 and as Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Ryan served as Vice President and Chief Financial Officer from April 2018 at Innovus Pharmaceuticals, Inc. until Aytu's acquisition of Innovus in February 2020. From August 2013 to April 2018, Ryan served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, where he also served as Chief Financial Officer of Medicinova, Inc. Ryan worked at Grant Thornton LLP, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Ryan received his B.S./B.A., Accounting and Finance from Georgetown University and is a Certified Public Accountant (inactive). 공시 • Nov 07
Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024 Aytu BioPharma, Inc. announced that they will report Q1, 2025 results After-Market on Nov 13, 2024 Reported Earnings • Sep 27
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: US$2.86 loss per share (improved from US$5.11 loss in FY 2023). Revenue: US$81.0m (down 25% from FY 2023). Net loss: US$15.8m (loss narrowed 7.1% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is expected to decline by 8.2% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%. 공시 • Sep 20
Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024 Aytu BioPharma, Inc. announced that they will report Q4, 2024 results After-Market on Sep 26, 2024 공시 • Aug 07
An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU). An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024. Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products.
An unknown buyer completed the acquisition of Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU) on August 6, 2024. New Risk • Jun 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (US$17.4m market cap). Major Estimate Revision • May 22
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$83.6m to US$81.3m. Losses expected to increase from US$2.23 per share to US$2.49. Pharmaceuticals industry in the US expected to see average net income growth of 3.3% next year. Consensus price target of US$8.00 unchanged from last update. Share price rose 2.3% to US$3.13 over the past week. Reported Earnings • May 17
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$0.52 loss per share (improved from US$1.93 loss in 3Q 2023). Revenue: US$18.0m (down 21% from 3Q 2023). Net loss: US$2.89m (loss narrowed 60% from 3Q 2023). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is expected to decline by 9.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.4%. 공시 • May 14
Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024 Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024. Location: dorsey & whitney llp, 1400 wewatta street, suite 400, colorado 80202, , denver United States 공시 • May 10
Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024 Aytu BioPharma, Inc. announced that they will report Q3, 2024 results After-Market on May 15, 2024 Reported Earnings • Feb 16
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: US$0.04 loss per share (improved from US$2.15 loss in 2Q 2023). Revenue: US$22.9m (down 13% from 2Q 2023). Net loss: US$220.0k (loss narrowed 97% from 2Q 2023). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 84%. Revenue is expected to decline by 12% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.0%. 공시 • Feb 08
Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024 Aytu BioPharma, Inc. announced that they will report Q2, 2024 results After-Market on Feb 14, 2024 Price Target Changed • Dec 29
Price target decreased by 95% to US$5.00 Down from US$110, the current price target is provided by 1 analyst. New target price is 67% above last closing price of US$2.99. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$5.11 last year. 공시 • Nov 08
Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023 Aytu BioPharma, Inc. announced that they will report Q1, 2024 results After-Market on Nov 14, 2023 공시 • Oct 27
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement Aytu BioPharma, Inc. announced receipt of U.S. Food & Drug Administration (FDA) approval of the Cotempla XR-ODT® ("Cotempla") Prior Approval Supplement (PAS). This approval enables the transfer of manufacturing of Cotempla to the Company's third-party manufacturer and follows a similar achievement for Adzenys XR- ODT® ("Adzenys") which received PAS approval in April 2023. Aytu is committed to a consistent and orderly transition of production to the new manufacturing facility in the coming months to ensure adequate inventory is available to meet the recent surge in prescription growth experienced for both Adzenys and Cotempla. 공시 • Oct 01
Aytu BioPharma, Inc. announced delayed annual 10-K filing On 09/29/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Sep 28
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$5.11 loss per share (improved from US$74.95 loss in FY 2022). Revenue: US$107.4m (up 11% from FY 2022). Net loss: US$17.1m (loss narrowed 85% from FY 2022). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is expected to decline by 6.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 7.3%. 공시 • Sep 22
Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023 Aytu BioPharma, Inc. announced that they will report Q4, 2023 results After-Market on Sep 27, 2023 공시 • Jul 11
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement Aytu BioPharma, Inc. submitted the Cotempla XR-ODT®? ("Cotempla") Prior Approval Supplement (PAS) to the U.S. Food & Drug Administration (FDA). If approved, the PAS would enable Aytu to transfer the production of Cotempla to the Company's third-party manufacturer. The Company expects a six-month review of the PAS submission, which would enable FDA approval by late calendar 2023 or early calendar 2024. The Company previously announced the FDA approval of the Adzenys XR-ODT (Adzenys) site transfer PAS and has begun shifting Adzenys production to the Company's contract manufacturer. 공시 • Jun 14
Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million. Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,743,695
Price\Range: $1.84
Discount Per Security: $0.1288
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 430,217
Price\Range: $1.8399
Discount Per Security: $0.1288 Breakeven Date Change • Jun 10
Forecast to breakeven in 2025 The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2024. The company is expected to make a profit of US$8.20m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Major Estimate Revision • May 18
Consensus EPS estimates fall by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$108.1m to US$102.8m. Losses expected to increase from US$4.78 per share to US$6.24. Pharmaceuticals industry in the US expected to see average net income decline 7.8% next year. Consensus price target of US$70.00 unchanged from last update. Share price fell 14% to US$1.81 over the past week. Breakeven Date Change • May 15
Forecast to breakeven in 2024 The 2 analysts covering Aytu BioPharma expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of US$900.0k in 2024. Average annual earnings growth of 149% is required to achieve expected profit on schedule. 공시 • Feb 16
Aytu BioPharma, Inc. announced delayed 10-Q filing On 02/15/2023, Aytu BioPharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 26
Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance Aytu BioPharma, Inc. (the Company or "Aytu") announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement. On January 23, 2023, Nasdaq confirmed in that for the ten consecutive business days, from January 6, 2023 to January 20, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and the matter is closed. 공시 • Jan 11
Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply Disruption. Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available. As the only FDA-approved Orally Disintegrating Tablet bioequivalent to Adderall XR, Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII is bridging the access gap resulting from the current supply disruption, as well as the shortage of Adderall IR. Aytu BioPharma, Inc. Adzenys XR-ODT is available as a potential treatment option to Adderall XR in six equivalent strengths. As healthcare insurance resets in January, many ADHD patients with high deductibles may face another challenge in accessing their medication. However, patients facing insurance challenges can gain access to Adzenys XR-ODT via Aytu's proprietary RxConnect program and the company's network of more than 1,000 retail pharmacies. The program is designed specifically to help patients navigate complex treatment journeys. It enables affordable, predictable patient access to Aytu Rx products and reduces out-of-pocket costs by 50 percent. In most cases, commercially insured patients will pay no more than $35 for their monthly prescription of Adzenys XR-ODT. Major Estimate Revision • Nov 21
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -US$0.49 to -US$0.22 per share. Revenue forecast steady at US$109.0m. Pharmaceuticals industry in the US expected to see average net income growth of 4.5% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 11% to US$0.23 over the past week. Breakeven Date Change • Nov 16
Forecast to breakeven in 2025 The analyst covering Aytu BioPharma expects the company to break even for the first time. New forecast suggests losses will reduce by 74% per year to 2024. The company is expected to make a profit of US$2.80m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule. Reported Earnings • Nov 16
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.057 loss per share (improved from US$1.09 loss in 1Q 2022). Revenue: US$27.7m (up 26% from 1Q 2022). Net loss: US$2.88m (loss narrowed 90% from 1Q 2022). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in the US. Major Estimate Revision • Oct 04
Consensus estimates of losses per share improve by 28% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from US$107.1m to US$110.1m. EPS estimate increased from -US$0.68 per share to -US$0.49 per share. Pharmaceuticals industry in the US expected to see average net income decline 2.3% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 2.6% to US$0.19 over the past week. Reported Earnings • Sep 28
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: US$3.75 loss per share (further deteriorated from US$3.48 loss in FY 2021). Revenue: US$96.7m (up 47% from FY 2021). Net loss: US$110.2m (loss widened 89% from FY 2021). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 4.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in the US. Major Estimate Revision • May 23
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$2.23 to -US$3.82 per share. Revenue forecast of US$94.5m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$11.00 to US$8.00. Share price rose 16% to US$0.56 over the past week. Reported Earnings • May 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$1.79 loss per share (down from US$1.41 loss in 3Q 2021). Revenue: US$24.2m (up 80% from 3Q 2021). Net loss: US$53.1m (loss widened 109% from 3Q 2021). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 337%. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in the US. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Feb 22
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$106.8m to US$94.5m. EPS estimate increased from -US$2.54 to -US$2.36 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$11.00 unchanged from last update. Share price rose 6.5% to US$1.32 over the past week. Reported Earnings • Feb 15
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: US$0.44 loss per share (up from US$0.72 loss in 2Q 2021). Revenue: US$23.1m (up 53% from 2Q 2021). Net loss: US$11.5m (loss widened 21% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 24%. Over the next year, revenue is forecast to grow 37%, compared to a 17% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Price Target Changed • Jan 25
Price target decreased to US$11.00 Down from US$17.40, the current price target is provided by 1 analyst. New target price is 824% above last closing price of US$1.19. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.54 next year compared to a net loss per share of US$3.48 last year. Reported Earnings • Nov 18
First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$21.9m (up 62% from 1Q 2021). Net loss: US$27.9m (loss widened US$23.5m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 28
Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020) The company reported a decent full year result with improved revenues, although losses increased and control over costs was weaker. Full year 2021 results: Revenue: US$65.6m (up 138% from FY 2020). Net loss: US$58.3m (loss widened 328% from FY 2020). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Board Change • Sep 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 08
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gary Cantrell was the last director to join the board, commencing their role in 2016. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Executive Departure • Sep 01
Independent Director Steven Boyd has left the company On the 30th of August, Steven Boyd's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. 
